Physician profile
Alison Fleig
NPI 1013312693
$47,828.74
in general payments reported to CMS, 2019-2025
43 companies · $8,138 in 2025
The $8,138 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $10K · 2023: $7,457 · 2024: $8,229 · 2025: $8,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $4,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,421.00 |
| Food and Beverage | $4,401.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $20,366.56 | 2021-2023 | Omnipod |
| Medtronic, INC. | $15,562.79 | 2021-2025 | Minimed 780g, Minimed 770g |
| Tandem Diabetes Care, INC. | $6,060.64 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,094.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $708.69 | 2021-2025 | Jardiance, Mounjaro, Lyumjev |
| Dexcom, INC. | $554.24 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $374.80 | 2022-2025 | Tepezza, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.98 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $347.84 | 2021-2025 | Korlym |
| Antares Pharma, INC. | $271.72 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Recordati_rare_diseases_inc. | $199.40 | 2022-2025 | Isturisa, Signifor Lar |
| Novartis Pharmaceuticals Corporation | $188.26 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $166.93 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $144.85 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $139.29 | 2022-2025 | Afrezza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $123.02 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $122.66 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $103.63 | 2021-2022 | |
| Halozyme INC | $85.58 | 2023 | |
| Nevro Corp. | $82.69 | 2023-2024 | Senza |
| Vivus LLC | $76.68 | 2022-2024 | Qsymia |
| Esperion Therapeutics, INC. | $76.62 | 2022-2025 | Nexletol |
| Ascendis Pharma Endocrinology INC | $71.50 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $61.04 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $57.04 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.35 | 2022-2024 | |
| Radius Health, INC. | $45.51 | 2023-2025 | Tymlos |
| Embecta Corp. | $41.79 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Kyowa Kirin, INC. | $41.61 | 2024-2025 | Crysvita |
| Abbvie INC. | $34.93 | 2022-2023 | |
| Tolmar, INC. | $28.67 | 2024-2025 | Jatenzo |
| Zealand Pharma US, INC. | $19.85 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $19.42 | 2025 | Imcivree |
| Alexion Pharmaceuticals, INC. | $19.22 | 2024 | Strensiq |
| Becton, Dickinson and Company | $19.11 | 2022 | |
| Neurocrine Biosciences, INC. | $17.70 | 2025 | |
| Eusa Pharma (US) LLC | $17.43 | 2022 | |
| Averitas Pharma INC. | $17.05 | 2025 | Qutenza |
| Beta Bionics, INC. | $15.19 | 2024 | Ilet Bionic Pancreas |
| Acella Pharmaceuticals, LLC | $14.25 | 2025 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $12.67 | 2022 | |
| Alvogen INC | $11.92 | 2022 | |
| Cequr Corporation | $11.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Fleig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.